Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab ( (GMAB) ) has issued an update.
On August 12, 2025, Genmab A/S announced a capital increase of 4,563 shares following the exercise of employee warrants, raising approximately DKK 4.7 million. This increase, which represents about 0.01% of the company’s share capital, will be listed on Nasdaq Copenhagen and reflects Genmab’s ongoing commitment to enhancing its financial structure and supporting its strategic growth initiatives.
The most recent analyst rating on (GMAB) stock is a Hold with a $24.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the most significant factors driving the high score. The company’s robust profitability, strategic pipeline advancements, and positive market outlook contribute to its strong position. Technical analysis and valuation also support the stock’s potential, although short-term technical signals are mixed.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, specializing in innovative and differentiated antibody therapeutics. Established in 1999, the company focuses on developing next-generation antibody technology platforms and has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 1,326,010
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.